Bristol-Myers Squibb Company (BMY) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $56.53, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining.
Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, generating $48.2B in total 2025 revenues. The US accounts for 69% of revenues with key products including Eliquis, Opdivo,... Read more
Hold if already holding. Not a fresh buy at $56.53, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining. Chart setup: RSI 44 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: conservative.
Recent developments
updated 2026-06-15Recent Developments — Bristol-Myers Squibb Company
Latest news
- NEWS Do Wall Street Analysts Like Bristol-Myers Squibb Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow - StockStory — StockStory neutral
- NEWS Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts - Yahoo Finance — Yahoo Finance positive
- NEWS Bristol-Myers Squibb: Vestmo Stock of the Week - Barron's — Barron's positive
- NEWS Cantor Fitzgerald raises Bristol-Myers Squibb stock price target to $54 - Investing.com — Investing.com positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States69%10-K Item 1: 'United States| 69 | %'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $56.53, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining. Chart setup: RSI 44 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $56.77 (+0.4%), stop $53.68 (−5.3%), A.R:R 0.1:1. Score 5.7/10, moderate confidence.
Take-profit target: $56.77 (+0.4% upside). Target $56.77 (+0.4%), stop $53.68 (−5.3%), A.R:R 0.1:1. Stop-loss: $53.68.
Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.3): -1.5.
Bristol-Myers Squibb Company trades at a P/E of 16.0 (forward 9.3). TrendMatrix value score: 7.4/10. Verdict: Hold.
36 analysts cover BMY with a consensus score of 3.5/5. Average price target: $63.
What does Bristol-Myers Squibb Company do?Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology,...
Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, generating $48.2B in total 2025 revenues. The US accounts for 69% of revenues with key products including Eliquis, Opdivo, Revlimid, and growth portfolio drugs. Multiple products face patent expiry pressures and the IRA's maximum fair price for Eliquis took effect January 1, 2026.